Dividends & Buybacks ·
Collegium Pharmaceutical announced the execution of an accelerated share repurchase agreement with Jefferies LLC to…
COLLCollegium Pharmaceutical, Inc
Collegium Pharmaceutical announced the execution of an accelerated share repurchase agreement with Jefferies LLC to buy back $50 million of its common stock. The company paid $50 million upfront and received an initial delivery of 1,556,420 shares based on a closing price of $25.70 on August 12, 2026. This transaction represents approximately 80% of the expected total repurchase under this specific agreement, with final settlement expected by the fourth quarter of 2026. The purchase is part of a broader $150 million share repurchase program authorized in July 2025. As of June 30, 2026, there were approximately 32.5 million shares outstanding. Collegium Pharmaceutical operates in the pharmaceutical industry and develops commercial-stage medicines for pain management.